Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer


Creative Commons License

KARABULUT B. , KARACA B., VAROL U., MUSLU U., ÇAKAR B. , Atmaca H., ...Daha Fazla

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, cilt.29, 2010 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 29
  • Basım Tarihi: 2010
  • Doi Numarası: 10.1186/1756-9966-29-102
  • Dergi Adı: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Özet

Background: Ovarian cancer is the most fatal gynecologic malignancies in the world. Although, platinum based treatments are widely used, the disease becomes treatment refractory within two years, and novel treatment options should be searched. All-trans retinoic acid (ATRA) induces growth arrest, differentiation and cell death in some types of cancer cells and its combination with various anticancer agents results in enhanced cytotoxicity. Zoledronic acid is a common bisphosphonate known for its anticancer effects beyond its current use in the treatment of cancer-induced bone disease. We aimed to investigate the possible additive/synergistic effect of both agents in OVCAR-3 and MDAH-2774 ovarian cancer cell lines, since both agents show superiority to conventional cytotoxics in terms of adverse events.